Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jun 6;6:26420.
doi: 10.1038/srep26420.

A Novel Biomarker Panel for Irritable Bowel Syndrome and the Application in the General Population

Affiliations
Free PMC article

A Novel Biomarker Panel for Irritable Bowel Syndrome and the Application in the General Population

Zlatan Mujagic et al. Sci Rep. .
Free PMC article

Abstract

Biological markers that measure gut health and diagnose functional gastro-intestinal (GI) disorders, such as irritable bowel syndrome (IBS), are lacking. The objective was to identify and validate a biomarker panel associated with the pathophysiology of IBS that discriminates IBS from healthy controls (HC), and correlates with GI symptom severity. In a case-control design, various plasma and fecal markers were measured in a cohort of 196 clinical IBS patients and 160 HC without GI symptoms. A combination of biomarkers, which best discriminates between IBS and HC was identified and validated in an independent internal validation set and by permutation testing. The correlation between the biomarker panel and GI symptom severity was tested in IBS patients and in a general population cohort of 958 subjects. A set of 8 biomarker panel was identified to discriminate IBS from HC with high sensitivity (88.1%) and specificity (86.5%). The results for the IBS subtypes were comparable. Moreover, a moderate correlation was found between the biomarker panel and GI symptom scores in the IBS (r = 0.59, p < 0.001) and the general population cohorts (r = 0.51, p = 0.003). A novel multi-domain biomarker panel has been identified and validated, which correlated moderately to GI symptom severity in IBS and general population subjects.

Figures

Figure 1
Figure 1. The final 8-item biomarker panel.
The length of the bar, i.e. positive or negative regression coefficient level, indicates the relative importance of the specific marker within the biomarker panel. Positive markers are decreased in IBS patients compared to HC, and vice versa for the negative markers.
Figure 2
Figure 2. Box plot representing the total score obtained for the 8-item biomarker panel for the IBS and HC group.
The total score was obtained by multiplying the real concentration of measured biomarkers in the validation set by the regression coefficient per marker (Fig. 1). It represents the probability of being IBS or HC.
Figure 3
Figure 3. ROC curve, with an area under the curve (AUC) of 0.89 for the discrimination between IBS patients and HC in the validation set, using the final 8-item biomarker panel.

Similar articles

See all similar articles

Cited by 9 articles

See all "Cited by" articles

References

    1. Bischoff S. C. ‘Gut health’: a new objective in medicine? BMC Med 9, 24, doi: 10.1186/1741-7015-9-24 (2011). - DOI - PMC - PubMed
    1. Canavan C., West J. & Card T. The epidemiology of irritable bowel syndrome. Clin Epidemiol 6, 71–80, doi: 10.2147/CLEP.S40245 (2014). - DOI - PMC - PubMed
    1. Magro F. et al. . European consensus on the histopathology of inflammatory bowel disease. J Crohns Colitis 7, 827–851, doi: 10.1016/j.crohns.2013.06.001 (2013). - DOI - PubMed
    1. Ludidi S. et al. . Markers for visceral hypersensitivity in patients with irritable bowel syndrome. Neurogastroenterol Motil 26, 1104–1111, doi: 10.1111/nmo.12365 (2014). - DOI - PubMed
    1. Corsetti M., Van Oudenhove L. & Tack J. The quest for biomarkers in IBS-where should it lead us? Neurogastroenterol Motil 26, 1669–1676, doi: 10.1111/nmo.12475 (2014). - DOI - PubMed

Publication types

LinkOut - more resources

Feedback